<DOC>
	<DOCNO>NCT00261027</DOCNO>
	<brief_summary>This project pilot , phase II , open-label , single-center , non-comparative clinical study evaluate antitumor efficacy tolerability exemestane treat adult post-menopausal woman recurrent refractory , stage II-IV , epithelial ovarian cancer . To evaluate efficacy tolerability exemestane population , patient enrol single site , namely Ottawa Regional Cancer Center . Patients select accord criterion outline receive exemestane ( 25 mg/day give orally daily ) disease progression study withdrawal . These patient treat out-patient basis . There specific wash-out time require patient previously receive either cis carboplatinum ; however , previous therapy must stop upon patient inclusion trial . In 1st stage less 2/15 patient achieve response study terminate . In 2nd stage great 7/28 patient achieve response investigation drug warranted.Treatment ( include drug dosage ) A commercial supply exemestane ( Aromasin ) provide . The medication administer patient home ( 25 mg take orally daily disease progression ) The medication take day meal time day . There patient diary need patient record time administration .</brief_summary>
	<brief_title>Aromasin ( Exemestane ) Patients With Recurrent Refractory Stage II - IV Epithelial Ovarian Cancer</brief_title>
	<detailed_description>This project pilot , phase II , open-label , single-center , non-comparative clinical study evaluate antitumor efficacy tolerability exemestane treat adult post-menopausal woman recurrent refractory , stage II-IV , epithelial ovarian cancer . To evaluate efficacy tolerability exemestane population , patient enrol single site , namely Ottawa Regional Cancer Center . Patients select accord criterion outline receive exemestane ( 25 mg/day give orally daily ) disease progression study withdrawal . These patient treat out-patient basis . There specific wash-out time require patient previously receive either cis carboplatinum ; however , previous therapy must stop upon patient inclusion trial . In 1st stage less 2/15 patient achieve response study terminate . In 2nd stage great 7/28 patient achieve response investigation drug warrant . Treatment ( include drug dosage ) A commercial supply exemestane ( Aromasin ) provide . The medication administer patient home ( 25 mg take orally daily disease progression ) The medication take day meal time day . There patient diary need patient record time administration .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>· Patients age 18 year older document diagnosis metastatic , stage IIIV , epithelial ovarian cancer histological/cytological confirmation disease.· Patients must oophorectomized postmenopausal ( i.e . menses within last 12 month ) .· Patients objective evidence measurable disease accord modified RECIST guideline . If measurable disease present , must CA 125 level ³ 30 U/mL combination nonmeasurable disease and/or ascites.· Patients may designate : · First line patient either refuse qualify initial therapy standard ci carboplatin + paclitaxel.· Refractory progression chemotherapy , relapse within 12 month final chemotherapy ( maximum 2 line chemotherapy treatment ) · Recurrent relapse beyond 12 month final chemotherapy ( maximum 2 line chemotherapy treatment ) · In patient receive radiation therapy , least 4 week must pass subsequent cessation radiation therapy , prior baseline assessment study.· Patients ECOG performance status 0 , 1 2 life expectancy &amp; gt ; 3 months.· Patients must adequate haematological ( WBC ³ 4000/mL , neutrophils ³ 2000/mL , platelet ³ 100,00/mL ) , hepatic ( total bilirubin £ 1.5 x upper limit normal ( ULN ) , AST/ALT £ 3 x ULN ) ) renal ( serum creatinine &amp; lt ; 1.5 X ULN ) organ functions.· Patients must give write informed consent sign prior registration . Known hypersensitivity exemestane· Participation another clinical study within thirty day prior treatment study . Concurrent treatment experimental drug anticancer therapy.· Patients rapidly progressive disease hormonal therapy may indicated.· Concomitant malignancy except adequately treat carcinoma situ uterine cervix basal squamous cell carcinoma skin . Patients malignancy must disease free least 5 years.· Patients metastatic disease central nervous system , eg . Paraneoplastic cerebellar degeneration , metastatic medulloblastoma , intramedullary spinal cord involvement , etc.· Patients receive prior hormonal therapy ovarian cancer include tamoxifen aromatase inhibitors.· Patients concurrent disease , opinion Investigator , would make patient inappropriate entry study.· Patients accessible treatment followup schedule hour participate center .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>ovarian cancer</keyword>
</DOC>